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A number of patients with benign prostatic hyperplasia can not undergo surgical therapy because of
advanced age, concomitant diseases, and other reasons. Since 1980, various types of urethral stents have
been used for high-risk patients with benign prostatic hyperplasia. We report our experience with the use of
urethral stents (Memotherm○R ). Between July 2002 and December 2010, we implanted urethral stents in 36
patients. The average follow-up period was 24.0 months. After stent implantation, 34 of the 36 patients
were able to micturate. The average residual urine volume was 24.7 ml (0-250 ml), and the maximal
urinary flow rate was 10.7 ml/s (3-24 ml/s). One stent had to be removed due to bladder tamponade, and
one had to be exchanged due to dislocation. In 2 patients, a stone formed at the bladder end of the stent,
and one of these patients underwent transurethral lithotripsy. Our results suggest that therapy with the
Memotherm○R urethral stent is a good option for patients suffering from urinary retention due to benign
prostatic hyperplasia.
(Hinyokika Kiyo 58 : 13-16, 2012)
























































排尿可能群でそれぞれ平均 67.8 ml (20.8∼128 ml），
平均 69.5 ml (32.4∼128 ml），平均 58.0 ml (20.8∼
126 ml) であった．
合併症は脳梗塞 4例，認知症 3例，パーキンソン病
1例，小脳失調症 1例，糖尿病 2例，心疾患 9例（狭
心症 2例，心筋梗塞 5例，その他 2例），腰椎ヘルニ
ア 1例，大腿骨骨折 1例，肝細胞癌 1例，腎細胞癌 1
例，慢性腎不全 1例であった．
神経疾患を合併したのは全体で10例，尿閉群は 8
Table 1. Patients characteristics
Total Urinary retention Able to void
No pts 36 26 (72.2％) 10 (27.8％)
Average age (range) 81.9 (70-92) 81.7 (70-92) 82.6 (78-87)
Performance status
2 26 18 8
3 10 8 2
ASA score
2 30 22 8
3 6 4 2
Prostate volume (ml) (range) 67.8 (20.8-128) 69.5 (32.4-128) 58.0 (20.8-126)
Neurologic concomitant disease 10 (27.8％) 8 (30.8％) 2 (20.0％)
Anesthesia
General 31 (86.1％) 23 8
Spinal 3 (8.3％) 2 1
Caudal 2 (5.6％) 1 1
Mean stent length (mm) 31.7 (15-50) 32.2 30.5
Table 2. Results
After stent placement (average) 6 months 1 year
Residual volume (ml) 55.4 (0-402) n＝31 24.7 (0-250) n＝26 52.2 (0-335) n＝18
Qmax (ml/s) 9 (4-13) 10.7 (3-24) 9.8 (4-24)
Qmin (ml/s) 3.9 (2-6) n＝13 5.4 (2-16) n＝18 5.3 (2-16) n＝11
IPSS 18.6 (16-28) n＝5 12.1 (3-24) n＝8 10.8 (3-24) n＝5
QOL 2.1 (0-5) n＝8
Table 3. Additional therapy ; urinary retention
Case No 年 齢 PS PV (ml) 合併症 時 期 内 容 原 因
1 71 3 不明 糖尿病，脳梗塞 直 後 CIC 尿 閉
2 79 2 59.2 脳梗塞 10カ月 CIC 尿 閉
3 82 3 44 パーキンソン病，心筋梗塞 26カ月 TUR-P 尿 閉
4 89 3 74.7 肺 癌 22カ月 尿道カテーテル 肺癌ターミナル
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Fig. 1. Results ; urinary retention.
れ25例（96.2％），21例（80.8％）であった．処置が
























Table 4. Results ; able to void
Preoperative (average) 6 months No
Residual volume (ml) 185.8 (4.2-640) 54.2 (0-402.4) 8 NS
Qmax (ml/s) 5.8 (2-10) 8.5 (3-13) 6 0.0149
Qmin (ml/s) 2 (1-3) 3.8 (2-6) 6 0.0218
IPSS 19.8 (15-24) 16 (10-22) 5 NS









































値は 11.8 ml，最大尿流率は 15.8 ml/s，IPSS は3.5に
改善したと報告している．また Gesenburg ら6) は，
123例の前立腺肥大症患者で，留置前後で残尿が平均
で 153.7 ml から 26.0 ml に，最大尿流率は 7.4 ml/s
から 16.1 ml/s に改善したと報告している．われわれ
の報告は残尿量，最大尿流率，IPSS の改善が悪かっ
た．理由としては，尿流量測定の際の排尿量が平均
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